Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR | P11473 | 12/20 | 0.61 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.56 |
| ▸ | PGR | P06401 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12047755 | 1.00 | VDR (0.61) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL12464943 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL12535671 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL12397908 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL25447329 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL24066861 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL17354891 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL6945983 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL21836180 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A | |
| Paricalcitol SCHEMBL14491013 | 0.94 | VDR (0.68) | VDRNR1I2PGRMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9212136-B2 | Methods for producing paricalcitol | AZAD PHARMACEUTICALS INGREDIENTS AG (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20110184199-A1 | Methods For Producing Paricalcitol | AZAD PHARMA AG (CH) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184199-A1 | Methods For Producing Paricalcitol | CYP2R1, PTH1R, CYP24A1 | VDR 18/4885NR1I2 4034/4885PGR 3674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.